Jasper Therapeutics (Jasper Therapeutics) EBIT per Share : $-6.12 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics EBIT per Share?

Jasper Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-1.13. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.12.

During the past 3 years, the average EBIT per Share Growth Rate was -129.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Jasper Therapeutics's EBIT per Share or its related term are showing as below:

JSPR' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -129.3 Med: -129.3 Max: -129.3
Current: -129.3

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Jasper Therapeutics was -129.30% per year. The lowest was -129.30% per year. And the median was -129.30% per year.

JSPR's 3-Year EBIT Growth Rate is ranked worse than
97.7% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs JSPR: -129.30

Jasper Therapeutics's EBIT for the three months ended in Mar. 2024 was $-15.07 Mil.

Jasper Therapeutics EBIT per Share Historical Data

The historical data trend for Jasper Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics EBIT per Share Chart

Jasper Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-5.47

-32.34

-140.26

-65.96

Jasper Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial										-1.59	-1.63	-1.77	-1.59	-1.13

Jasper Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Jasper Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-68.861	/	1.044
=	-65.96

Jasper Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-15.072	/	13.335
=	-1.13

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.12

Jasper Therapeutics (NAS:JSPR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Jasper Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Jasper Therapeutics (Jasper Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065

Website

https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Executives

Thomas G Wiggans	director
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal	officer: Chief Operating Officer	C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell	director, officer: President, CEO & Director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French	director	C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster	director, 10 percent owner	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel	10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p.	10 percent owner	350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade	10 percent owner	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004